updated 5/9/2011 2:48:01 PM ET 2011-05-09T18:48:01

MONTREAL, May 9, 2011 (GLOBE NEWSWIRE) -- A5 Laboratories Inc. (OTCBB:AFLB), a Biotechnology company, by developing novel immune therapeutic applications of interferon therapy to treat cancer and infectious diseases, is pleased to announce that it has begun production of bovine interferon on a small scale of 3 to 4 thousand units per day.

Interferon (IFN) is a type of protein called a cytokine that is secreted by cells of the body during an infection. It can inhibit viruses from spreading to neighboring cells and it can aid to eliminate harmful pathogens such as E.Coli and other bacteria present in livestock.

Interferons have many effects on the cells in the body. When a virus has infected cells in a tissue or organ, interferon protects neighboring uninfected cells and halts the spread of the virus. Interferon therapy stimulates the release of enzymes that interfere with protein synthesis and thereby destroys virus-infected cells.

The International Federation for Animal Health (IFAH) expects global demand for animal protein to rise by 50% by 2020; as the world's population grows, the need for better disease control is essential.

Richard Anazi, President and CEO stated, "Our Intention is to continue to increase the production and research capabilities for our interferons in our production facility." He went on to state: "This is a very important step to improve bovine production and keep antibiotics out of the food supply chain in the U.S. and Worldwide."

About A5 Labs: (OTCBB:AFLB)A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization. More information about the Company is available at its corporate website at www.a5labs.com. For more information, visit their corporate fact sheet http://premierstocks.tv/images/company_links/A5.pdf

Safe Harbor Statement: Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to A5 or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5's products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5's expansion efforts, economic conditions in the industry and the financial strength of A5's customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

CONTACT: Investor inquiries:
         Premier Media Service Inc.,
         Kelly Black
         1-480-649-8224 or

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com